HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Caroline Robert Selected Research

Vomiting

5/2015Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
7/2013Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
1/2012Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Caroline Robert Research Topics

Disease

250Melanoma (Melanoma, Malignant)
05/2024 - 03/2004
162Neoplasms (Cancer)
02/2024 - 03/2004
37Neoplasm Metastasis (Metastasis)
03/2024 - 03/2004
19Disease Progression
01/2021 - 06/2011
12Fatigue
10/2021 - 06/2009
12Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2021 - 08/2009
11Brain Neoplasms (Brain Tumor)
01/2024 - 11/2012
11Fever (Fevers)
11/2023 - 02/2013
9Basal Cell Carcinoma (Rodent Ulcer)
10/2023 - 12/2019
9Exanthema (Rash)
01/2023 - 02/2009
9Nausea
10/2021 - 06/2011
7Colitis
01/2023 - 05/2015
7Body Weight (Weight, Body)
11/2016 - 08/2010
7Keratoacanthoma
01/2015 - 08/2009
6Diarrhea
10/2021 - 06/2009
6Lymphatic Metastasis
11/2020 - 10/2010
6Neutropenia
06/2020 - 11/2012
5Myocarditis (Carditis)
05/2024 - 05/2015
5Pain (Aches)
02/2024 - 03/2009
5Dermatitis
12/2023 - 01/2012
5Hepatitis
11/2023 - 01/2018
5Carcinogenesis
01/2023 - 10/2011
5Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2023 - 06/2016
5Inflammation (Inflammations)
01/2022 - 02/2002
5Renal Cell Carcinoma (Grawitz Tumor)
10/2014 - 03/2007
4Skin Neoplasms (Skin Cancer)
05/2023 - 03/2011
4Hypertension (High Blood Pressure)
11/2022 - 02/2009
4Arthralgia (Joint Pain)
01/2020 - 06/2011
3Sarcoidosis (Schaumann Disease)
06/2022 - 10/2021
3COVID-19
01/2022 - 01/2020
3Alopecia (Baldness)
10/2021 - 02/2009
3Myalgia
10/2018 - 08/2015
3Vomiting
05/2015 - 01/2012
3Hemangioma (Angioma)
02/2012 - 11/2009
3Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
04/2009 - 08/2004
2Myositis (Idiopathic Inflammatory Myopathies)
05/2024 - 05/2018

Drug/Important Bio-Agent (IBA)

65IpilimumabIBA
02/2024 - 08/2010
60pembrolizumabIBA
03/2024 - 07/2013
55Immune Checkpoint InhibitorsIBA
02/2024 - 07/2013
42Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
04/2024 - 01/2012
30NivolumabIBA
05/2024 - 01/2015
28dabrafenibIBA
01/2023 - 11/2012
28trametinibIBA
01/2023 - 07/2012
25VemurafenibIBA
04/2024 - 06/2011
25Biomarkers (Surrogate Marker)IBA
01/2023 - 03/2007
18Dacarbazine (DIC)FDA LinkGeneric
11/2020 - 06/2009
17Monoclonal AntibodiesIBA
01/2020 - 08/2008
16AntibodiesIBA
12/2023 - 03/2004
13encorafenibIBA
04/2024 - 09/2017
13Proteins (Proteins, Gene)FDA Link
01/2023 - 01/2012
13Sorafenib (BAY 43-9006)FDA Link
04/2014 - 03/2007
12binimetinibIBA
04/2024 - 01/2018
11L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
05/2023 - 01/2016
10AntigensIBA
10/2022 - 03/2004
10LigandsIBA
01/2019 - 02/2002
9InterferonsIBA
10/2022 - 10/2010
9Phosphotransferases (Kinase)IBA
01/2021 - 07/2005
8B7-H1 AntigenIBA
01/2023 - 12/2016
7DNA (Deoxyribonucleic Acid)IBA
01/2023 - 04/2008
7Eukaryotic Initiation Factor-4F (EIF4F)IBA
01/2023 - 09/2014
6cobimetinibIBA
12/2023 - 01/2019
5atezolizumabIBA
12/2023 - 03/2014
5Mitogen-Activated Protein KinasesIBA
10/2022 - 04/2014
5CTLA-4 AntigenIBA
10/2021 - 08/2009
4sonidegibIBA
06/2023 - 10/2021
4Creatine Kinase (Creatine Phosphokinase)IBA
01/2023 - 01/2018
4Messenger RNA (mRNA)IBA
02/2022 - 10/2015
4Immune Checkpoint ProteinsIBA
02/2022 - 08/2014
4HhAntag691IBA
01/2022 - 12/2019
4Temozolomide (Temodar)FDA LinkGeneric
01/2014 - 06/2009
4Peptides (Polypeptides)IBA
09/2013 - 03/2005
4Imatinib Mesylate (Gleevec)FDA Link
02/2013 - 08/2004
4Sunitinib (Sutent)FDA Link
02/2009 - 01/2006
3SteroidsIBA
01/2024 - 10/2017
3RNA (Ribonucleic Acid)IBA
12/2023 - 01/2019
3MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA
01/2023 - 01/2012
3ChemokinesIBA
01/2023 - 06/2011
3CytokinesIBA
01/2023 - 06/2016
3Protein Isoforms (Isoforms)IBA
12/2022 - 08/2004
3Lipase (Acid Lipase)FDA Link
11/2022 - 11/2012
3spartalizumabIBA
01/2022 - 10/2020
3Programmed Cell Death 1 ReceptorIBA
01/2022 - 01/2019
3Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
11/2020 - 10/2019
3Alanine Transaminase (SGPT)IBA
01/2020 - 11/2016
3Paclitaxel (Taxol)FDA LinkGeneric
01/2019 - 06/2009
3tremelimumabIBA
06/2017 - 08/2008
3Microphthalmia-Associated Transcription FactorIBA
01/2017 - 04/2008
3Immunologic Adjuvants (Immunologic Adjuvant)IBA
01/2017 - 09/2008
3InterleukinsIBA
06/2016 - 02/2013
3Tyrosine Kinase InhibitorsIBA
01/2015 - 01/2006
2Bispecific AntibodiesIBA
12/2023 - 10/2022

Therapy/Procedure

138Therapeutics
03/2024 - 11/2004
70Immunotherapy
04/2024 - 03/2004
18Drug Therapy (Chemotherapy)
01/2022 - 11/2004
9Radiotherapy
11/2021 - 11/2009
6Lymph Node Excision (Lymph Node Dissection)
10/2022 - 01/2018
3Aftercare (After-Treatment)
02/2024 - 03/2011
3Ligation
01/2022 - 11/2014
3Duration of Therapy
11/2020 - 03/2009
3Intravenous Infusions
01/2019 - 11/2016